Sarah Cannon/Colorado Blood Cancer Institute
Denver, Colorado, United States
Cancer treatment center in Denver, Colorado
1721 E 19th Ave ste 200-300, Denver, CO 80218
About Sarah Cannon/Colorado Blood Cancer Institute
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Allogene Therapeutics
2
Cellectis S.A.
1
Karyopharm Therapeutics Inc
1
Nurix Therapeutics, Inc.
1
Rubius Therapeutics
1
Syros Pharmaceuticals
1
Clinical Trials at Sarah Cannon/Colorado Blood Cancer Institute
During the past decade, Sarah Cannon/Colorado Blood Cancer Institute conducted 7 clinical trials. In the 10-year time frame, 7 clinical trials started and 0 clinical trials were completed, i.e. on
average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 0 clinical trials were completed. i.e. 0%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Selinexor and Backbone Treatments of Multiple Myeloma Patients
2015-10-01
2025-01-01
Active, not recruiting
518
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
2019-09-23
2027-12-01
Recruiting
132
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
2019-11-21
2024-12-11
Recruiting
18
RTX-240 Monotherapy and in Combination With Pembrolizumab
2020-05-06
2022-11-30
Terminated
69
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
2021-05-05
2023-11-01
Recruiting
160
Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed AML
2021-08-26
2024-04-01
Recruiting
95
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
2021-06-06
2027-01-01
Recruiting
136
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Sarah Cannon/Colorado Blood Cancer Institute" #1 sponsor was "Allogene Therapeutics" with 2 trials, followed by "Cellectis S.A." with 1 trials
sponsored, "Karyopharm Therapeutics Inc" with 1 trials sponsored, "Nurix Therapeutics, Inc." with 1 trials sponsored and "Rubius Therapeutics"
with 1 trials sponsored. Other sponsors include -4 different institutions and
companies that sponsored additional 6 trials in total.
Clinical Trials Conditions at Sarah Cannon/Colorado Blood Cancer Institute
According to Clinical.Site data, the most researched conditions in "Sarah Cannon/Colorado Blood Cancer Institute" are
"Relapsed/Refractory Multiple Myeloma" (3 trials), "Acute Myeloid Leukemia" (1 trials), "Chronic Lymphocytic Leukemia (CLL)" (1 trials), "Diffuse Large B-cell Lymphoma (DLBCL)" (1 trials) and "Follicular Lymphoma (FL)" (1 trials). Many other conditions were trialed in "Sarah Cannon/Colorado Blood Cancer Institute" in a lesser frequency.
Clinical Trials Intervention Types at Sarah Cannon/Colorado Blood Cancer Institute
Most popular intervention types in "Sarah Cannon/Colorado Blood Cancer Institute" are "Drug" (6 trials), "Biological" (3 trials) and "Genetic" (2 trials). Other intervention types were less common.
The name of intervention was led by "ALLO-647" (2 trials), "Cyclophosphamide" (2 trials), "Fludarabine" (2 trials), "ALLO-605" (1 trials) and "ALLO-715" (1 trials). Other intervention names were less common.
Clinical Trials Genders at Sarah Cannon/Colorado Blood Cancer Institute
The vast majority of trials in "Sarah Cannon/Colorado Blood Cancer Institute" are
7 trials for "All" genders.
Clinical Trials Status at Sarah Cannon/Colorado Blood Cancer Institute
Currently, there are NaN active trials in "Sarah Cannon/Colorado Blood Cancer Institute".
undefined are not yet recruiting,
5 are recruiting,
1 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were undefined completed trials in Sarah Cannon/Colorado Blood Cancer Institute,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Sarah Cannon/Colorado Blood Cancer Institute, 6 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 0 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".